From Brazilian Jiu-Jitsu to baked goods, here are 16 updates on businesses in the Lake Travis-Westlake area. Now open AMP ...

If cuticle cutting or pushing gives you the heebie-jeebies (understood ... (They're the brand I keep going back to.) ...

CLR, metal scrubbing pads, vinegar, and many other things ... that one beat-up Ziploc you've used for going on three years now! Feeling accomplished at cutting down waste: check! Promising reviews: "I ...

Chanel and Louis Vuitton are reshaping Swiss watchmaking, acquiring top manufacturers and captivating luxury watch collectors ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in a trial, the company said Tuesday. In the phase 3 study ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...